Literature DB >> 23750085

Molecule of the month: miRNA and Parkinson's disease protein PARK2.

Paul Shapshak1.   

Abstract

Entities:  

Year:  2013        PMID: 23750085      PMCID: PMC3670118          DOI: 10.6026/97320630009381

Source DB:  PubMed          Journal:  Bioinformation        ISSN: 0973-2063


× No keyword cloud information.
Parkinson's disease is generally associated with aging, i.e. elderly individuals. We are gaining many deep insights into neuropathogenesis in Parkinson's disease and there are many publications on this topic; we briefly mention a few as they relate to the increasingly studied miRNAs. Parkinson's disease results from protein inclusions or Lewy bodies and destruction of (mid-brain) substantia nigra pars compacta neurons that are dopaminergic. A novel approach to investigate molecular processes in human diseases as well as in normal control and function is through the study of miRNAs. miRNAs are increasingly associated with many diseases and in Parkinson's disease [1, 2]. Up-regulation, beige Regulation, purple Co-expression, brown Physical Interaction, turquoise dotted Predicted Protein Interaction, and mauve dotted Predicted TFactor Regulation (GenePro SA Biosciences, http://www.sabiosciences.com/). Additional studies used a bioinformatics and computational approach to the analysis of gene expression using the Gene Expression Omnibus database at NIH [3]. They then predicated Parkinson's disease associated transcription factors, miRNAs, and identified 11 genes that include a new transcription factor, N-Myc down-regulated gene 1 (NDRG1) and junction plakoglobin (JUP).In Parkinson's disease, NDRG1 is regulated by miRNA-133 [4]. miRNA profile analysis indicated miR-34b and miR-34c decreased expression. These changes were found in the substantia nigra, frontal cortex, cerebellum, and amygdala. In aneuroblastoma cell culture line, depletion of miR-34b or miR- 34c resulted in cell death. In addition, depletion of these miRNAs resulted in decreased expression of Parkin or parkinson protein 2 (Park2) and parkinson protein 7 (DJ1). These cellular changes appear to result in mitochondrial dysfunction in Parkinson's disease [2]. Figure 1 shows an interactive network diagram of input neighbors to Park2 (parkin) and Figure 2 shows an interactive network diagram of input proteins from Figure 1 (Park2, CASK, SNCAIP, HSPA4, STUB1, SIM2, CBL, LIMK1, PACRG, SEPT5, PSMA7, and BAG5). It is left as a puzzle for the interested reader to identify the various genes and their functions in the figures [5-7].
Figure 1

Network of input protein (Park2) with immediate interactive proteins. In this figure, line-colors and various interactions with other genes are red Down-regulation, green Up-regulation, beige Regulation, purple Co-expression, brown Physical Interaction, turquoise dotted Predicted Protein Interaction, and mauve dotted Predicted TFactor Regulation (GenePro SA Biosciences, http://www.sabiosciences.com/).

Figure 2

Network of input proteins from Figure 1(Park2, CASK, SNCAIP, HSPA4, STUB1, SIM2, CBL, LIMK1, PACRG, SEPT5, PSMA7, BAG5) and showing additional neighbors of these proteins (up to 100 total). In this figure, line-colors and various interactions with other genes are red Down-regulation, green Up-regulation, beige Regulation, purple Co-expression, brown Physical Interaction, turquoise dotted Predicted Protein Interaction, and mauve dotted Predicted TFactor Regulation (5- GenePro SA Biosciences, http://www.sabiosciences.com/).

  3 in total

Review 1.  MicroRNAs: possible role in pathogenesis of Parkinson's disease.

Authors:  E V Filatova; A Kh Alieva; M I Shadrina; P A Slominsky
Journal:  Biochemistry (Mosc)       Date:  2012-08       Impact factor: 2.487

2.  Identification of regulatory relationships in Parkinson's disease.

Authors:  Hao Wang; Cheng Sun; Yusi Liang; Heying Zhang; Yonggang Tan
Journal:  J Mol Neurosci       Date:  2013-02-21       Impact factor: 3.444

3.  MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function.

Authors:  Elena Miñones-Moyano; Sílvia Porta; Georgia Escaramís; Raquel Rabionet; Susana Iraola; Birgit Kagerbauer; Yolanda Espinosa-Parrilla; Isidre Ferrer; Xavier Estivill; Eulàlia Martí
Journal:  Hum Mol Genet       Date:  2011-05-10       Impact factor: 6.150

  3 in total
  3 in total

Review 1.  Tiny But Mighty: Promising Roles of MicroRNAs in the Diagnosis and Treatment of Parkinson's Disease.

Authors:  Ying Wang; Zhaofei Yang; Weidong Le
Journal:  Neurosci Bull       Date:  2017-07-31       Impact factor: 5.203

2.  In Silico Analysis of SNPs in PARK2 and PINK1 Genes That Potentially Cause Autosomal Recessive Parkinson Disease.

Authors:  Yousuf Hasan Yousuf Bakhit; Mohamed Osama Mirghani Ibrahim; Mutaz Amin; Yousra Abdelazim Mirghani; Mohamed Ahmed Salih Hassan
Journal:  Adv Bioinformatics       Date:  2016-12-29

Review 3.  Advances with microRNAs in Parkinson's disease research.

Authors:  Liuqing Ma; Liangming Wei; Fei Wu; Zhenhua Hu; Zhenguo Liu; Weien Yuan
Journal:  Drug Des Devel Ther       Date:  2013-10-01       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.